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Editorial
Transcatheter treatment of severe mitral regurgitation in Brazil: a new kid on 
the block
Tratamento transcateter da insuficiência mitral grave no Brasil: uma novidade na área
While moderate-to-severe and severe mitral regurgitation (MR) 
lead to high rates of morbidity and mortality if no intervention is 
performed, a considerable number of patients are exclusively med-
ically managed due to their high surgical risk;1 indeed, adverse 
event rates among high-risk patients whom undergo mitral valve 
surgery are relevant.2 Therefore, there is a large unmet need for 
transcatheter therapies in this setting.1 In this edition of Revista 
Brasileira de Cardiologia Invasiva, Brito Jr. et al.3 describe the first 
two percutaneous edge-to-edge mitral valve repairs utilizing the 
MitraClip™ (Abbott Vascular, Abbott Park, USA) device performed 
in Brazil. We would like to congratulate the authors for their pio-
neering work in this important field. 
While the only randomized trial published to date comparing 
MitraClip™ implantation with mitral valve surgery included mostly 
(~ 70%) patients with primary (i.e., degenerative) MR, the scenario in 
which mitral valve surgery delivers excellent results,4 large real 
world registries, such as ACCESS-EU,5 GRASP,6 and TRAMI,7 included 
mostly patients with secondary (i.e., functional) MR, ref lecting 
the potential of also utilizing MitraClip™ in the setting in which 
mitral valve surgery delivers worse results, such as lack of sur-
vival benefit and high rates of recurrence coupled with high mor-
bidity and mortality.2 Randomized trials comparing MitraClip™ 
implantation with mitral valve surgery for patients with severe 
functional MR, such as the ongoing COAPT (Clinical Outcomes As-
sessment of the MitraClipTM Percutaneous Therapy for High Surgi-
cal Risk Patients; NCT01626079) study, will certainly shed more 
light on the ideal approach for this particular subset of patients. 
We believe, however, that the approval of MitraClip™ for both 
primary and secondary MR in Brazil was extremely mature and 
important as it relied not only on randomized data, which could 
restrict its indications for primary MR, but also on large real-
world experiences that included thousands of patients with func-
tional MR (i.e., those with the higher likelihood of receiving no 
surgical intervention)1 whom were successfully treated, mostly 
demonstrating sustained long-term results. 
Increasing experience has enabled the expansion of Mitra-
Clip™ indications, which were initially limited by the strict 
echocardiographic criteria proposed in the EVEREST II study.5 In 
fact, while our group was a pioneer in the implantation of this 
novel device in Italy back in 2008, we also recently demonstrat-
ed the potential for expanding the indications to more complex 
anatomical scenarios, while maintaining favorable outcomes.6,8 
While predictors of acutely unsuccessful MitraClip™ procedure 
have been demonstrated by Lubos et al.,9 we identif ied long-
term predictors of unfavorable clinical outcomes after Mitra-
Clip™ implantation,10 which ultimately enabled a more refined 
understanding of this intervention. Importantly, however, the 
learning curve associated with MitraClip™ may be relatively 
steep; therefore, following the echocardiographic criteria ini-
tially proposed by the EVEREST II study4 may be the best way to 
start a new program while progressively transitioning to more 
complex scenarios.
MitraClip™ implantation is associated with hemodynamic 
improvement, left ventricle reverse remodeling, and improve-
ment in quality of life. When reduction of MR to ≤ 2+ is achieved, 
the procedure can be considered successful, just as demonstrat-
ed in the two cases described by Brito Jr. et al.3 Importantly, one 
should not expect that MR will be completely abolished with 
MitraClip™; in fact, improvement in quality of life was compara-
ble in patients with 1+ and 2+ MR post-procedure in a recent 
analysis of the EVEREST II study.11
Similarly to transcatheter aortic valve implantation, struc-
tural heart intervention centers that include MitraClip™ in their 
armamentarium will certainly observe an increase in the overall 
rates of referrals for mitral valve dysfunction evaluation; there-
fore, not only transcatheter but also surgical mitral valve inter-
ventions will likely increase (i.e., "halo effect"). This may become 
even more important when reimbursement for the MitraClip™ 
procedure is an issue. For example, while expected for the sec-
ond semester of 2015, to date in the United States there is no full 
coverage for MitraClip™ implantation. Nonetheless, this fact has 
not stopped centers of excellence from adopting this novel tech-
nique, thereby offering a broader spectrum of structural heart 
disease interventions to their patients.
While MitraClip™ is the only Food and Drug Administration-
approved transcatheter procedure to treat severe MR, tran-
scatheter balloon expandable aortic valves have been implanted 
in the mitral position to treat dysfunctional surgical bioprosthe-
sis and annuloplasty rings12 with promising results; in addition, 
native mitral valves with important annular calcification have 
also been treated in a similar fashion.13 While these interven-
tions probably represent the only therapeutic option for prohib-
itive surgical risk patients, the ultimate goal in this field is the 
possibility of implanting dedicated transcatheter heart valves in 
the mitral position. Several different devices are currently being 
tested, but the initial human experience is still in its infancy. 
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